Device Trial Radar · NCT07539324
Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCAD
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
892
Planned (sponsor's estimate)
Start
Sep 28, 2026
Primary completion
Dec 31, 2030
Study completion Dec 31, 2032
Sponsor
- Lead sponsor
- Genoss Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 20, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aimes to compare the clinical outcomes of drug-coated balloon-based percutaneous coronary intervention (DCB-based PCI) and drug-eluting stent-based percutaneous coronary intervention (DES-based PCI) in patients with multivessel coronary artery lesions measuring 2.25 mm to 4.0 mm in diameter through a prospective, multicenter, active-controlled, randomized, investigator-initiated clinical trial.
Conditions
- Multi Vessel Coronary Artery Disease
- Percutaneous Coronary Intervention
Interventions
GENOSS® DCB (Paclitaxel-coated PTCA balloon catheter)Device
GENOSS DCB is designed to improve the lumen diameter and to reduce restenosis in the treatment of lesions in native coronary arteries. GENOSS DCB has been demonstrated to reduce restenosis for the treatment of in-stent restenosis and de-novo lesions in coronary arteries narrowed by atherosclerosis. GENOSS DCB is designed to improve the lumen diameter and to reduce restenosis in the treatment of lesions in native coronary arteries. GENOSS DCB has been demonstrated to reduce restenosis for the treatment of in-stent restenosis and de-novo lesions in coronary arteries narrowed by atherosclerosis. GENOSS DCB's active drug coating is located on the surface of the balloon, which contains 3ug Paclitaxel per 1mm2. The drug is embedded in a physiologically harmless and degradable delivery matrix (main component: shellac and vitamin E-TPGS).
Contemporary Drug-Eluting Stents (DES)Device
Contemporary drug-eluting stents (DES) with either biodegradable or non-biodegradable (durable) polymer coatings, covering all regulatory-approved, thin-strut metal platforms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Net Clinical outcome (NCO)Time frame: the time to the first occurrence of a Net Clinical Outcome (NCO) within 12 months after randomization.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ulsan University Hospital
Ulsan, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.